-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ZIVO Bioscience (OTCMKTS:ZIVO) Stock Crosses Above Fifty Day Moving Average of $3.72
ZIVO Bioscience (OTCMKTS:ZIVO) Stock Crosses Above Fifty Day Moving Average of $3.72
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.72 and traded as high as $3.93. ZIVO Bioscience shares last traded at $3.80, with a volume of 5,352 shares trading hands.
ZIVO Bioscience Stock Down 0.8 %
The company's 50 day moving average price is $3.72 and its 200 day moving average price is $3.55.
Get ZIVO Bioscience alerts:Institutional Inflows and Outflows
An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. boosted its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,468 shares of the biotechnology company's stock after acquiring an additional 15,147 shares during the quarter. Vanguard Group Inc. owned 0.98% of ZIVO Bioscience worth $359,000 at the end of the most recent quarter. Institutional investors own 5.54% of the company's stock.
ZIVO Bioscience Company Profile
(Get Rating)ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Further Reading
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe's Stands Out Amid Q2 Retail Reports
- Target's Results Cap Upside Potential For Retail Stocks
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.72 and traded as high as $3.93. ZIVO Bioscience shares last traded at $3.80, with a volume of 5,352 shares trading hands.
Zivo Bioscience，Inc.(場外交易市場代碼：Zivo-GET評級)在週三的交易中超過了50日移動均線。該股的50日移動均線切入位為3.72美元，最高交易價格為3.93美元。Zivo Bioscience的股票最新報3.80美元，成交量為5352股。
ZIVO Bioscience Stock Down 0.8 %
Zivo Bioscience股價下跌0.8%
The company's 50 day moving average price is $3.72 and its 200 day moving average price is $3.55.
該公司的50日移動均線價格為3.72美元，其200日移動均線價格為3.55美元。
Institutional Inflows and Outflows
機構資金流入和流出
An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. boosted its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,468 shares of the biotechnology company's stock after acquiring an additional 15,147 shares during the quarter. Vanguard Group Inc. owned 0.98% of ZIVO Bioscience worth $359,000 at the end of the most recent quarter. Institutional investors own 5.54% of the company's stock.
一家機構投資者最近提高了對Zivo Bioscience股票的頭寸。先鋒集團(Vanguard Group Inc.)在最近一次向美國證券交易委員會(Securities&Exchange Commission)披露的信息中稱，該公司第一季度將其在Zivo Bioscience，Inc.(場外交易市場代碼：Zivo-GET)的頭寸提高了19.6%。該機構投資者在本季度額外購買了15,147股後，持有這家生物技術公司的92,468股股票。截至最近一個季度末，先鋒集團持有Zivo Bioscience 0.98%的股份，價值35.9萬美元。機構投資者持有該公司5.54%的股份。
ZIVO Bioscience Company Profile
Zivo生物科學公司簡介
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Zivo Bioscience，Inc.是一家研發公司，致力於向動物、人類、膳食補充劑和醫用食品製造商許可和銷售從其專有藻類培養物中提取的天然生物活性成分。它在生物技術和農業技術部門開展業務，擁有知識產權組合，包括專有藻類和細菌菌株、生物活性分子和複合體、生產技術、栽培技術，以及應用於人類和動物健康的專利或正在申請專利的發明。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe's Stands Out Amid Q2 Retail Reports
- Target's Results Cap Upside Potential For Retail Stocks
- 免費獲取StockNews.com關於Zivo生物科學的研究報告(Zivo)
- 哪些半導體類股準備好迎接價格大幅波動？
- 儘管面臨更廣泛的經濟挑戰，礦商的收益仍在上漲
- 安捷倫科技對Illumina證明瞭自己的價值
- Lowe‘s在第二季度零售報告中脱穎而出
- 塔吉特的業績上限零售類股的上行潛力
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Zivo生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zivo Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧